CA2094512A1 - Polypeptides de fusion - Google Patents

Polypeptides de fusion

Info

Publication number
CA2094512A1
CA2094512A1 CA002094512A CA2094512A CA2094512A1 CA 2094512 A1 CA2094512 A1 CA 2094512A1 CA 002094512 A CA002094512 A CA 002094512A CA 2094512 A CA2094512 A CA 2094512A CA 2094512 A1 CA2094512 A1 CA 2094512A1
Authority
CA
Canada
Prior art keywords
ala
leu
tyr
seq
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002094512A
Other languages
English (en)
Inventor
Teresa M. Kubiak
Satish K. Sharma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2094512A1 publication Critical patent/CA2094512A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57536—Endothelin, vasoactive intestinal contractor [VIC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002094512A 1990-12-13 1991-12-12 Polypeptides de fusion Abandoned CA2094512A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62672790A 1990-12-13 1990-12-13
US626,727 1990-12-13

Publications (1)

Publication Number Publication Date
CA2094512A1 true CA2094512A1 (fr) 1992-06-14

Family

ID=24511577

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002094512A Abandoned CA2094512A1 (fr) 1990-12-13 1991-12-12 Polypeptides de fusion

Country Status (13)

Country Link
EP (1) EP0561971A1 (fr)
JP (1) JPH06503473A (fr)
AU (1) AU662508B2 (fr)
CA (1) CA2094512A1 (fr)
CZ (1) CZ109393A3 (fr)
FI (1) FI932680A0 (fr)
HU (1) HUT69963A (fr)
IE (1) IE914347A1 (fr)
NO (1) NO932148L (fr)
RU (1) RU2114119C1 (fr)
SK (1) SK60893A3 (fr)
TW (1) TW213923B (fr)
WO (1) WO1992010576A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9906715D0 (en) * 1999-03-23 1999-05-19 Ferring Bv Compositions for promoting growth
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
EP1052286A3 (fr) * 1999-04-12 2001-07-25 Pfizer Products Inc. Preparations contenant l'hormone de croissance GH et l'hormone libérant l'hormone de croissance GHRH
US6759393B1 (en) 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
MXPA02005014A (es) 1999-11-19 2003-02-27 Transkaryotic Therapies Inc Constructo de acido nucleico para produccion optimizada de productos.
GB0010188D0 (en) * 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
EP1205551A1 (fr) * 2000-11-09 2002-05-15 Pfizer Products Inc. Préparations contenant l'hormone de croissance GH et l'hormone libérant l'hormone de croissance GHRH
WO2002079415A2 (fr) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reduction de l'immunogenicite de proteines de fusion
DK1454138T3 (da) * 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
GB2384001B (en) * 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins
EP2298337B1 (fr) 2003-12-09 2017-02-22 Novo Nordisk A/S Régulation des préférences alimentaires en utilisant des agonistes du GLP-1
EP1758575A1 (fr) 2004-06-11 2007-03-07 Novo Nordisk A/S Remede contre l'obesite induite par les medicaments au moyen d'agonistes glp-1
KR20070115947A (ko) 2005-02-11 2007-12-06 아밀린 파마슈티칼스, 인크. 선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
AU2007223855B2 (en) † 2006-03-06 2013-05-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
CA2771999A1 (fr) 2009-08-24 2011-03-10 Amunix Operating Inc. Compositions de facteurs de coagulation vii et procedes de preparation et d'utilisation de celles-ci
EP2573103B1 (fr) * 2010-01-29 2017-07-05 Archer-Daniels-Midland Company Domaines peptidiques se liant à de petites molécules d'importance industrielle
EP2822577B1 (fr) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Protéines de facteur viii de recombinaison
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
SG11201912433YA (en) * 2017-06-29 2020-01-30 Ureka Sarl Pro-drug peptide with improved pharmaceutical properties
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) * 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4569794A (en) * 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process
US4734399A (en) * 1985-08-06 1988-03-29 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
CA1340522C (fr) * 1987-03-10 1999-05-04 Heinz Dobeli Proteins hybrides renfermant des histidines voisines pour une purification amelioree
ATE113965T1 (de) * 1989-06-16 1994-11-15 Upjohn Co Stabilisierte, starke grf-analoga.
DE69120409T2 (de) * 1990-04-09 1996-11-28 Upjohn Co Verfahren zur reinigung von rekombinanten proteinen und dafür nützliche produkte

Also Published As

Publication number Publication date
CZ109393A3 (en) 1994-01-19
HU9301705D0 (en) 1993-10-28
EP0561971A1 (fr) 1993-09-29
FI932680L (fi) 1993-06-11
IE914347A1 (en) 1992-06-17
NO932148L (no) 1993-08-09
NO932148D0 (no) 1993-06-11
HUT69963A (en) 1995-09-28
WO1992010576A1 (fr) 1992-06-25
RU2114119C1 (ru) 1998-06-27
FI932680A7 (fi) 1993-06-11
FI932680A0 (fi) 1993-06-11
TW213923B (fr) 1993-10-01
JPH06503473A (ja) 1994-04-21
AU9116591A (en) 1992-07-08
AU662508B2 (en) 1995-09-07
SK60893A3 (en) 1993-10-06

Similar Documents

Publication Publication Date Title
CA2094512A1 (fr) Polypeptides de fusion
CA2367856C (fr) Analogues de peptides d'inhibition gastrique et leur application au traitement du diabete
AU693815B2 (en) Enzymatic method for modification of recombinant polypeptides
Campbell et al. Rational design, synthesis, and biological evaluation of novel growth hormone releasing factor analogues
US20090062192A1 (en) Dimeric Peptide Agonists of the Glp-1 Receptor
EP0871474B2 (fr) Production d'insuline humaine
JPS60155196A (ja) 成長ホルモン放出因子類似物
WO2005058954A1 (fr) Nouveaux composes de glp-1
KR20070085224A (ko) Ｇｌｐ-1을 포함하는 트랜스페린 융합 단백질을 사용하는혼합 요법
US7566691B2 (en) Vasoactive intestinal polypeptide pharmaceuticals
JP2002506792A (ja) Ｎ末端修飾ｇｌｐ−１誘導体
NZ338004A (en) Process for producing peptide with glucagon like peptide-1 (GLP-1) activity by incorporating a protective and helper component to facilitate purification
US20060234933A1 (en) Vasoactive intestinal polypeptide pharmaceuticals
EP0381433B1 (fr) Méthode de production de glucagon
Chunxiao et al. Study on preparation and activity of a novel recombinant human parathyroid hormone (1–34) analog with N-terminal Pro–Pro extension
EP0511003B1 (fr) Analogues superactifs du facteur libérant l'hormone de croissance
CN111087475A (zh) Fgf21融合蛋白及抑制其降解的方法
HU211572A9 (hu) Fúziós polipeptidek. Az átmeneti oltalom az 1-38. igénypontra vonatkozik
HUT63857A (en) Process for producing grf-analogs
JPH0394682A (ja) ペプチドの製造法

Legal Events

Date Code Title Description
FZDE Discontinued